化疗港植入患者增强胸部CT上可模拟椎体转移的椎体静脉淤血
单中心回顾性研究分析1079例化疗港植入患者增强胸部CT,椎体静脉淤血(VVC)患病率5.8%,结节型VVC患病率1.5%,均伴椎体静脉反流,结节倾向于位于骨皮质下,对侧臂注射造影剂后70%消失,贝伐珠单抗使用与VVC独立相关。
要点
- 化疗港植入患者中结节型VVC患病率1.5%,平均大小5.9±3.1 mm、衰减784±162 HU,倾向位于骨皮质下,需与椎体转移鉴别。
- 结节型VVC均伴椎体静脉反流,67%的VVC患者存在无名静脉狭窄。
- 对侧臂注射造影剂后70%(31/44)的VVC消失,有助于鉴别。
核心结论
- 化疗港植入患者中VVC及结节型VVC患病率低,结节型VVC均伴椎体静脉反流且倾向位于骨皮质下,为避免VVC首选对侧臂注射造影剂。
研究设计与样本
- 回顾性单中心研究,基于2016年1月至2016年12月1412例成人化疗港植入患者的随访增强胸部CT,排除333例后分析1079例(平均年龄62.3±11.6岁,女性540例)。
关键影像表现/征象
- 结节型VVC平均大小5.9±3.1 mm、衰减784±162 HU,倾向于位于骨皮质下;所有VVC患者(63/63)均显示椎体静脉反流,67%(42/63)伴无名静脉狭窄。
临床应用与阅片要点
- 对侧臂注射造影剂后70%(31/44)的VVC消失,作者认为为避免VVC首选对侧臂注射造影剂。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to determine the prevalence of vertebral venous congestion (VVC) in patients with chemoport insertion, evaluate the imaging characteristics of nodular VVC, and identify the factors associated with VVC.
MATERIALS AND METHODS: This retrospective single-center study was based on follow-up contrast-enhanced chest computed tomography (CT) of 1412 adult patients who underwent chemoport insertion between January 2016 and December 2016. The prevalence of venous stenosis, reflux, and VVC were evaluated. The imaging features of nodular VVC, including specific locations within the vertebral body, were analyzed. To identify the factors associated with VVC, patients with VVC were compared with a subset of patients without VVC who had been followed up for > 3 years without developing VVC after chemoport insertion. Toward this, a multivariable logistic regression analysis was performed.
RESULTS: After excluding 333 patients, 1079 were analyzed (mean age ± standard deviation, 62.3 ± 11.6 years; 540 females). The prevalence of VVC was 5.8% (63/1079), with all patients (63/63) demonstrating vertebral venous reflux and 67% (42/63) with innominate vein stenosis. The median interval between chemoport insertion and VVC was 515 days (interquartile range, 204-881 days). The prevalence of nodular VVC was 1.5% (16/1079), with a mean size of 5.9 ± 3.1 mm and attenuation of 784 ± 162 HU. Nodular VVC tended to be located subcortically. Forty-four patients with VVC underwent CT examinations with contrast injections in both arms; the VVC disappeared in 70% (31/44) when the contrast was injected in the arm contralateral to the chemoport site. Bevacizumab use was independently associated with VVC (odds ratio, 3.45; P < 0.001).
CONCLUSION: The prevalence of VVC and nodular VVC was low in patients who underwent chemoport insertion. Nodular VVC was always accompanied by vertebral venous reflux and tended to be located subcortically. To avoid VVC, contrast injection in the arm contralateral to the chemoport site is preferred.
引用
- Shin JI, Chee CG, Yoon MA, et al. Vertebral Venous Congestion That May Mimic Vertebral Metastasis on Contrast-Enhanced Chest Computed Tomography in Chemoport Inserted Patients. Korean J Radiol. 2024. PMID: 38184770. doi:10.3348/kjr.2023.0224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。